Research digest · doses studied
CJC-1295 dosage in the research literature
The doses, routes, and handling reported in published studies — described as research context, never as a recommendation. There is no approved human dose.
CJC-1295 dosage in the research literature
There is no approved human dosage of CJC-1295. What the published literature reports are the doses administered in research, and those are the only figures this page repeats. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [1][3]. In the GHRH-knockout mouse growth study, the dose was 2 micrograms per administration at 24-, 48-, or 72-hour intervals [4].
These are study doses in study settings, not a protocol. Community and clinic figures circulating online for the no-DAC Modified GRF (1-29) and for CJC-1295/ipamorelin pairings commonly cite fixed amounts in the 100 to 300 microgram range, but those numbers are not derived from controlled human trials and this site does not endorse them. The distinction matters: a published dose in a monitored pharmacokinetic study is evidence; a forum number is not.
What route was used in CJC-1295 studies?
Subcutaneous injection was the primary route across the human and animal studies [1][3][4]. Early GRF(1-29) pharmacokinetic work also used the intravenous route [12]. Oral bioavailability is negligible — CJC-1295 is a peptide and would be digested before absorption — which is why every study used injection. This describes the routes studied; it is not an administration instruction.
How much CJC-1295 should I take?
There is no approved human dose, so there is no answer this site can responsibly give. Human pharmacokinetic studies used single subcutaneous doses of 30, 60, or 90 micrograms per kilogram [1][3]; community figures are not derived from controlled trials. This page reports research doses only, and CJC-1295 is an unapproved research chemical.
How much CJC-1295 DAC should I take?
The DAC variant's multi-day half-life means a single dose elevates growth hormone and IGF-1 for days, so its dosing logic is fundamentally different from a short-acting peptide [1]. Published pharmacokinetic studies dosed 30 to 90 micrograms per kilogram subcutaneously [1][3]. No human dosing is approved, and protocols circulating online are not trial-derived.
How much CJC-1295 / ipamorelin should I take?
No approved human dose exists for CJC-1295, for ipamorelin, or for the combination. The GHRH-analog-plus-GHRP pairing is studied for supra-additive growth-hormone release, but published human dosing data are limited and combination protocols are not trial-validated. This site reports what studies administered, not what anyone should take.
How is CJC-1295 reconstituted in research handling?
In research handling, the lyophilized (freeze-dried) peptide is reconstituted with bacteriostatic water and kept refrigerated, per standard study and supplier handling notes. The four substitutions confer protease resistance, and in the DAC form the albumin conjugation confers the multi-day duration. Oral bioavailability is negligible — the peptide would be digested before absorption. This is laboratory-handling context, not a use instruction.
What the human clinical record actually contains
The human evidence base behind these doses is small, and it is worth being precise about its size. The pharmacokinetic studies in healthy volunteers established the GH and IGF-1 kinetics and the 5.8-to-8.1-day half-life [1][3], and a proteomics study added candidate biomarkers of axis activation [5]. That is essentially the human record: short-term, mechanism-focused, early-phase work.
There is no large efficacy trial and no long-term safety trial in healthy adults. A Phase 2 trial of the DAC form in HIV-associated visceral obesity was discontinued, and the long-acting development program did not advance. So when a dose figure circulates as a 'CJC-1295 protocol,' it is worth asking what it is grounded in — and for almost every figure beyond the published 30-to-90-microgram-per-kilogram pharmacokinetic doses, the honest answer is that it is not grounded in a controlled human trial at all.
Why dosing logic differs by form
Dosing logic is inseparable from half-life, which is why the DAC and no-DAC forms cannot share a schedule. The DAC form's multi-day half-life means a single dose produces a sustained, days-long GH/IGF-1 elevation [1] — the CJC-1295 DAC vs no-DAC page covers this in full. The short-acting no-DAC form, by contrast, produces a brief pulse and is associated in community use with more frequent administration.
None of that is a recommendation. It is the structural reason a single 'dose' number is meaningless without specifying the form, the route, and the study it came from. This page reports the doses studied — 30, 60, or 90 micrograms per kilogram subcutaneously in human pharmacokinetic work [1][3], and 2 micrograms per administration in the mouse growth study [4] — and stops there, because CJC-1295 is unapproved and a published study dose is not a personal regimen.